9th Tropé Meeting

Updates and Controversies in Gynecologic Oncology

Friday December 7, 2018
09:00 - 18:00

The auditorium in Building K
Institute for Cancer Research,
The Norwegian Radium Hospital

SPONSORED BY
INGER AND JOHN FREDRIKSEN FOUNDATION FOR OVARIAN CANCER RESEARCH
Welcome to the 9th Tropé meeting on updates and controversies in treatment of gynecologic oncology. This meeting would not have been possible without the generous support of the Inger and John Fredriksen foundation for ovarian cancer research.

We are entering a new era in the treatment of women with ovarian carcinoma, our armamentarium of therapeutics is growing. This last year we have seen results from trials on targeted therapies in gynecologic oncology with significant impact on survival. How will this affect or alter treatment strategies in regards to traditional medical and surgical therapies for these women, both in the primary and recurrent setting?

We are grateful to have Professor Andreas DuBois as our 9th Tropé lecturer this year. Despite advances in medical therapy, surgery remains the cornerstone in treatment of ovarian cancer. Will this hold true moving forward? Professor DuBois will share his thoughts on this topic.

Currently, there is an ongoing debate in regards to surgical management of early stage cervical cancer, propelled by a recent publication of the LACC trial in the NEJM. We have also seen new data during 2018 on HIPEC in ovarian carcinoma. We look forward to a pro-con debate discussing these topics with our speakers and participants.

Welcome to this exciting meeting. We hope that you will find the meeting both interesting and informative, and that it will shed light on hot topics in gynecologic cancer.

Claes Tropé & Ane Gerda Z Eriksson
Course Directors
### Scientific Program

#### Session 1: Developments in Ovarian Cancer
**Chair:** Professor Line Bjørge, MD, PhD, MBA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:05 - 09:35</td>
<td>New Developments in PARP Inhibitors in Ovarian Cancer</td>
<td>Mansoor Raza Mirza, MD (Denmark)</td>
</tr>
<tr>
<td>09:35 - 10:10</td>
<td>WBC BRCA1 Promoter Methylation and Ovarian Cancer Risk</td>
<td>Per E. Lønning, MD, PhD (Norway)</td>
</tr>
<tr>
<td>10:15 - 10:45</td>
<td>Immunotherapy in Ovarian Cancer Therapy, Hype or Hope?</td>
<td>Robert L. Coleman, MD (U.S.A.)</td>
</tr>
</tbody>
</table>

#### Session 2: Recurrent Ovarian Cancer
**Chair:** Anne Dørum, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10 - 11:35</td>
<td>Therapeutic Options and Survival in Women with Platinum Sensitive Recurrent EOC in Norway</td>
<td>Witold Szczesny MD, PhD (Norway)</td>
</tr>
<tr>
<td>11:35 - 12:10</td>
<td>The Role of Angiogenesis Inhibitors in Recurrent EOC</td>
<td>Robert L. Coleman, MD (U.S.A.)</td>
</tr>
</tbody>
</table>

#### Coffee Break

#### Session 3: HIPEC in Ovarian Cancer
**Chair:** Stein Larsen, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:05 - 14:35</td>
<td>Pro: Incorporating HIPEC in the Therapy of Ovarian Cancer</td>
<td>Oliver Zivanovic MD, PhD (USA)</td>
</tr>
<tr>
<td>14:35 - 15:05</td>
<td>Con: Is HIPEC Ready for Prime Time in Ovarian Cancer?</td>
<td>Andreas Du Bois MD, PhD (Germany)</td>
</tr>
<tr>
<td>15:05 - 15:15</td>
<td>Discussion</td>
<td>-</td>
</tr>
</tbody>
</table>

#### Session 4: Surgical Management of Early Stage Cervical Cancer
**Chair:** Bilal Sert, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 15:45</td>
<td>Pro: Minimally Invasive Surgery in Early Stage Cervical Cancer, the Danish Experience</td>
<td>Claus Hegdall, MD, PhD (Denmark)</td>
</tr>
<tr>
<td>15:45 - 16:15</td>
<td>Con: Minimally Invasive Surgery in Early Stage Cervical Cancer</td>
<td>Pedro Ramirez, MD (USA)</td>
</tr>
<tr>
<td>16:15 - 16:25</td>
<td>Discussion</td>
<td>-</td>
</tr>
</tbody>
</table>

#### Coffee Break

#### Session 5: Cellular Therapy in Ovarian Cancer, is the Future Bright?
**Chair:** Ben Davidson, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45 - 17:15</td>
<td>Dendritic Cell Vaccines in Ovarian Cancer, Reason to Be Optimistic?</td>
<td>Lukas Rob, MD, PhD (Czech Republic)</td>
</tr>
<tr>
<td>17:15 - 17:20</td>
<td>Discussion</td>
<td>-</td>
</tr>
<tr>
<td>17:20 - 17:50</td>
<td>The Danish Gynecologic Cancer Biobank, a Modern Day Fairy Tale</td>
<td>Estrid Hegdall, MD, PhD (Denmark)</td>
</tr>
<tr>
<td>17:50 - 17:55</td>
<td>Discussion</td>
<td>-</td>
</tr>
</tbody>
</table>

#### Closing Remarks
**Mansoor R Mirza, MD (Denmark)**
Mansoor Raza Mirza MD

Mansoor Raza Mirza, MD is Chief Oncologist at the Department of Oncology, Rigshospitalet, Denmark. Being both medical and radiation oncologist, and having main interest in gynecologic oncology, Dr. Mirza is involved in non-surgical treatment of gynecologic cancers. He is Medical Director of the Nordic Society of Gynaecological Oncology (NSGO), Executive Director of Gynecologic Cancer InterGroup (GCIG). He is Council member of European Society of Gynaecological Oncology (ESGO), faculty of ESMO, IGCS, ESGO, ESO and Vice-Chair of the Danish Gynecologic Cancer Group (DGCG). Dr Mirza has multiple publications including several publications in the New England Journal of Medicine (Citation Index 6853; H-Index 38).

Per Eystein Lønning MD

Per Eystein Lønning (born 1953) graduated from the University of Bergen (MD) in 1979. He became certified as a specialist in clinical oncology and radiotherapy in 1988, and received his PhD in cancer research in 1989. In 1990 he became consultant in oncology and head of the breast cancer section at the department of clinical oncology, Haukeland University Hospital in Bergen. In 1992 he became professor at the University of Bergen. His research activity has mainly focused on translation research in breast cancer. Initially concentrating on endocrine therapy with main focus on aromatase inhibition, over the recent years he and his group has concentrated on genomic work with emphasis on the mechanisms of resistance to chemotherapy and metastatic propagation. This work has involved other cancer forms, like colorectal cancer and melanoma in addition to breast cancer. He has also worked on projects centered on identifying genetic and epigenetic cancer risk mechanisms. His research activities have resulted in about 350 papers in journals with referee-service. His works are cited > 32.000 times, resulting in an H-score of 59 in the Web of Science. In 1999 he was granted the Olav V Norwegian national prize in Cancer Research, and in 2004 he was selected Scientist of the Year by the Norwegian Western Health Administration. He became a member of the Norwegian Academy of Science and Letters in 2010, and was elected Fellow of the European Academy of Cancer Sciences in 2014.

Witold Szczesny MD, PhD

Witold Szczesny, born 1960, Warsaw, Poland, has his medical education from The Medical Academy in Warsaw, Poland, 1986, Norwegian authorization between 1987 (course for the foreign physicians) and fulfillment of Norwegian internship in 1989 at Diakonissehets Hospital, Lovisenberg, Oslo, Norway. Witold Szczesny had been working four years as a general practitioner in North Norway and during between 1993 – 2012 at different departments University Hospitals receiving his training in Haukeland Hospital in Bergen, Norway, in Rigshospitalet and in Radiumhospital in Oslo, Norway and, recently, at The Sykehuset Innlandet Hospital Trust. Since 2012 Witold Szczesny has been engaged as PhD fellow in the project “Survival after treatment for epithelial ovarian cancer in Norway. A population-based register study”. This project was conducted in cooperation between The Research Dept., Sykehuset Innlandet Hospital Trust and The Cancer Registry of Norway with partial financial aid from John Fredriksens Fond for Ovarialcancer research at Norwegian Radiumhospital.

Robert L. Coleman MD

Dr. Coleman is Professor, in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas, M.D. Anderson Cancer Center and holds the Ann Rife Cox Chair in Gynecology and serves as Executive Director, Cancer Network Research. His research interests include drug discovery and novel therapeutics for ovarian, uterine, and cervical cancer, clinical trial development and statistical design. He is PI or co-PI for several CTEP-funded prospective clinical trials including those supporting the MDACC Ovarian and Uterine SPORES, as well as, several partnered pharmaceutical sponsored trials. He is a project lead on the MDACC Gynecologic Cancer Moonshot. Dr. Coleman has authored or coauthored over 500 scientific publications, including over 280 peer-reviewed original research articles. In 2015, he was served as President for the Society of Gynecologic Oncology and is currently the President-Elect of the International Gynecologic Cancer Society. He serves as co-Director of Gynecologic Oncology Group Partners and serves on the Board of Directors for the GOG Foundation.
Andreas du Bois, MD, PhD

Andreas du Bois, MD, PhD, is the director of the Department of Gynecologic Oncology & Gynecologic Oncology at the Kliniken Essen Mitte (KEM) in Essen, Germany. He was born in 1956, was married and is a widower since 2014, he has 3 children and currently 7 grandchildren.

Dr. du Bois received his medical degree from the Albert Ludwigs University of Freiburg Faculty of Medicine in 1987, performed his residency and registered as a fellow in gynecology & obstetrics in 1993. He completed his habilitation and was awarded venia legendi in gynecology from the University of Freiburg in 1997. Additionally, he was awarded venia legendi in gynecology from the University of Mainz in 2002.

Prior to assuming his current appointment at the KEM in 2010, for 11 years Dr du Bois was the chair of the Department of Gynecology and Gynecologic Oncology at the Horst Schmidt Klinik (HSK) in Wiesbaden, Germany.

Professor du Bois is a member of many medical societies, including the European Society of Gynecologic Oncology (ESGO), the International Society of Gynecologic Cancer (ISGC), the American Society of Clinical Oncology (ASCO), and the German Cancer Society (DKG). He served as officer / council member in ESGO and Gynecologic Cancer Intergroup (GOG) and was chair of the 3rd International Ovarian Cancer Consensus Conference (2004). He is co-founder and past-president of the European Network of Gynecologic Oncology Conference (2004). He is co-founder and past-president of the European Network of Gynecologic Oncology Trial groups (ENGOT) and founder and one of the chairpersons of AGO Study Group (formerly AGO-OVAR). He was the chair and/or initiator of many of the pivotal trials of the AGO in ovarian cancer among them the trials defining carboplatin-paclitaxel as frontline standard regimen, carboplatin-gemcitabine as 2nd line standard regimen, and almost all of the large surgical trials (LION on lymphadenectomy, ROBOT on borderline tumors, and the DEKSTOP I-III series evaluating surgery for recurrent ovarian cancer).

Oliver Zivanovic, MD, PhD

Oliver Zivanovic, MD, PhD, is currently on the faculty of Memorial Sloan Kettering Cancer Center (MSK) and Assistant Professor of the Weill Cornell Medical College and New York Hospital. I am the Institutional Principle Investigator for Gynecologic Oncology Group (GOG) Partners and NRG Oncology and the Director of Innovative Surgical Technology at MSK. I devoted my early research towards investigating pharmacokinetics of intraperitoneal drug delivery in patients with advanced ovarian cancer as well as patient-reported outcomes and electronic symptom-tracking in patients recovering from surgery and developing novel prognostic models for patients with uterine sarcomas. I am currently the PI of a randomized phase II trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin in patients with platinum-sensitive recurrent ovarian cancer and the PI of a prospective study evaluating electronic symptom monitoring in patients undergoing gynecologic cancer surgery.

Claus K. Høgdall, MD, PhD

My main scientific interest translational research was initiated 25 years ago and has been increasingly developed with initiation of several studies, a national gyn. cancer database (DGCD) and biobanks (MALOVA, Pelvic Mass, Endomet and more). Participates as investigator and initiator in several cancer studies (selected examples):

- The ovarian cancer (OC) study (MALOVA/MERMAID)
- CASA study (monitoring of chemotherapy treatment for OC)
- Head of DGCD
- The Pelvic Mass study and GOVEC groups
- Board member of the DGCG research group
- Member of the OC Association Consortia
- Member of Collaborative Ovarian, prostate and breast Gene-environment Study (COGS)

Dr. Pedro T. Ramirez is Professor in the Department of Gynecologic Oncology and Reproductive Medicine and Director of Minimally Invasive Surgical Research & Education. He is also the recipient of the David M. Gershenson Distinguished Professor in Ovarian Cancer Research Endowment and of the Randall Prize for Excellence in Cancer Treatment.

He has published a total of 219 manuscripts in peer-reviewed journals, including the New England Journal of Medicine and has published a total of 19 book chapters. In addition, he is the Editor for an upcoming textbook titled Principles of Gynecologic Oncology Surgery. Dr. Ramirez is also the Editor-in-Chief of the International Journal of Gynecological Cancer.

Dr. Ramirez is also the Chair of the Enhanced Recovery After Surgery (ERAS) Program in Gynecologic Oncology. He has published extensively on the subject of ERAS in numerable high-impact peer-reviewed journals. Of significant note, he co-authored the current Guidelines for ERAS Programs entitled “Guidelines for pre- and intraoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations-Part I”, and “Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations-Part II”. These guidelines were published in the journal Gynecologic Oncology in 2016 and since their publication, they have been downloaded over 31,000 times.

Dr. Ramirez is the Principal Investigator in the LACC Trial: A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy versus Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. The study accrued a total of 631 patients and was an international collaboration involving 33 sites throughout the world.
Prof. Lukas Rob, MD, PhD, born 1958 in the Czech Republic. He underwent training in Obstetrics and Gynecology, Medical Oncology and Oncogynecology at the 1st Medical Faculty of the Charles University in Prague. Academic Background: 1986 - 1996  Charles University - 1st. Medical Faculty, Prague 1, 1996 - 2016  Charles University - 2nd. Medical Faculty, Prague 5, 2016 - now Charles University - 3rd. Medical Faculty, Prague 10, CZ.

Prof. Rob was Head of the Department of Obstetrics and Gynecology (2002- 2015) 2nd Medical Faculty and a Chairmen of the Oncogynecology Center at University Hospital Motol. Since 2016 Head of the Department of Obstetrics and Gynecology 3rd Medical Faculty and a Chairmen of the Oncogynecology Center University Hospital Kralovske Vinohrady. Dr. Rob’s research is focused on gynecologic oncology, primarily in the area of women’s malignancies with particular emphasis on the cervical and vulvar cancer, sentinel lymph node mapping, fertility sparing surgery, ovarian cancer and gestational trophoblastic disease. He was a Council member IFCPC 1998 - 2002, Counsil member of ESGO (2002-2006), a Vice-president of ESGO (2006-2008). He was member of the Financial Committee IGCS (2006-2010), chair Local Organizing Committee 13th Biennial meeting IGCS 2010, and Member of Nomination committea IGCS - 2014-2016. Prof. Rob was counsil member Czech Gynecology and Obstetrics society (1998-2005), Czech Oncology Society (2000-2004) and president of the Czech Oncogynecological Society (2004 - 2018). Prof. Rob is lecturing locally and nationally on the treatment of women with gynecological cancer and published several original papers and reviews- H index 21, WOS citation 1442.

I am Clinical professor in molecular pathology at University of Copenhagen and Head of Molecular Unit, Department of Pathology. I am director of the Nationwide Bio –and GenomeBank Denmark which include Danish CancerBiobank (DCB), Danish RheumatologyBiobank (DRB), Danish Diabetes Biobank (DDB) and Danish BlooddonorBiobank (DBB). I am responsible for the management, guideline description and programming of the database module. More nationwide biobanks are planned. Career track records are documented in the areas: Molecular pathology, biobanking and various tumor profiling expression analyses. Special focus and experience in biomarkers of colorectal and ovarian tumors. I am attending Global Excellence through Department of Gynaecology and Oncology at Righospitalet with MD Anderson, Professor R. Bast. In this collaboration Molecular Unit will be partner and perform tissue micro arrays and different molecular analyses on sample material from both sites.

A prestigious Award, the King’s Medal of Merit has been awarded to professor emeritus Claes Tropé

Professor emeritus Claes Tropé, received the prestigious Norwegian award The King’s Medal of Merit on September 7, 2018. This award is given for extraordinary achievements of importance to the nation and society at large. We are very proud of professor Tropé, and warmly congratulate him!

With best greetings from the Department of Gynecologic Oncology

Erik Rokkones
Head of Department
Radium Hospital Foundation